AP NEWS

Selexis SA and Hoba Therapeutics Team Up to Advance Hoba’s Investigational Neuropathic Pain Treatment into the Clinic

September 26, 2018

GENEVA & COPENHAGEN, Denmark--(BUSINESS WIRE)--Sep 26, 2018--Selexis SA and Hoba Therapeutics announced today that they have entered into an agreement to advance the development of Hoba’s clinical candidate HB-086 (rhMeteorin) for the treatment of peripheral neuropathic pain. Under the agreement, Selexis is leveraging its proprietary SURE technology Platform to rapidly develop a stable, high-performance research cell bank (RCB) expressing HB-086, an endogenous protein found only in the nervous system. Hoba is working with Selexis to advance HB-086 into the clinic as part of a consortium of national and international partners funded by the Innovation Fund Denmark.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005109/en/

“It’s been fulfilling to work with Hoba as a cell line development partner that’s been able to successfully express viable levels of HB-086 in Chinese hamster ovary (CHO) cells,” said Marco Bocci, PhD, DPharm, Selexis vice president, licensing and business development. “We’re honored to be a part of the consortium working to move HB-086 into the clinic with the goal of making it available to physicians for the eventual treatment of patients. This population is in dire need of better treatment options and it’s exciting to have the opportunity to contribute to the next generation of pain management drugs.”

Selexis’ modular SURE technology  Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.

“Cell line developers utilizing more traditional approaches lack the benefits of Selexis’ technology and expertise, which we needed to advance HB-086. Selexis was able to overcome the challenges of expressing HB-086 and develop a research cell bank that makes it possible for us to enter clinical study quickly – and that’s great news given that many individuals experience debilitating pain,” said Hoba Therapeutics’ CEO Kenneth Petersen, MD, PhD. “It is our mission to introduce treatments that will bring relief to all patients who suffer from neuropathic pain without the risk of addiction – a benefit to themselves and society. Selexis is instrumental in helping us achieve this.”

About HB-086

HB-086 (recombinant human Meteorin) is a 31 kD secreted protein that promotes neurite outgrowth and glial differentiation in the central nervous system. Significant pain relieving properties of HB-086 have been demonstrated in several gold standard preclinical models and the effect is sustained for a significant period following cessation of treatment, demonstrating a disease modifying potential for the drug. Hoba Therapeutics is developing HB-086 as a treatment for peripheral neuropathy and associated pain.

About Selexis SA

Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 100 drug products in clinical development and the manufacture of three commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. In June 2017, Selexis became part of the JSR Life Sciences group. JSR’s CDMO service offering leverages the full capabilities of Selexis’ proprietary SURE technology Platform™ to offer an end-to-end solution to industry. More information is available at www.selexis.com.

About Hoba Therapeutics

Hoba Therapeutics is a world-class biopharmaceutical company dedicated to providing effective, safe and disease-modifying treatments to patients living with neuropathic pain and other neurological diseases. The company was established in 2017 with funding from Borean Innovation and Novo Seeds. For more information, please visit www.hobatherapeutics.com.

FOR MORE INFORMATION

- Web www.selexis.com - LinkedIn www.linkedin.com/company/selexis-sa - Twitter www.twitter.com/SelexisSA - Facebook www.facebook.com/SelexisSA

View source version on businesswire.com:https://www.businesswire.com/news/home/20180926005109/en/

CONTACT: Media Inquiries for Selexis

Sam Brown Inc.

Mike Beyer

+1 312-961-2502

mikebeyer@sambrown.com

or

Company Inquiries for Selexis

Robert Meister

Head, Corporate Communications

+1 602-953-1716

robert.meister@selexis.com

or

Media and Investor Inquiries for Hoba Therapeutics

Kenneth A Petersen

CEO

+45 3110 1285

keap@hobatherapeutics.com

KEYWORD: UNITED STATES EUROPE NORTH AMERICA DENMARK NEW YORK SWITZERLAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Selexis SA and Hoba Therapeutics

Copyright Business Wire 2018.

PUB: 09/26/2018 08:00 AM/DISC: 09/26/2018 08:01 AM

http://www.businesswire.com/news/home/20180926005109/en

AP RADIO
Update hourly